Data for Rivaroxaban presented at the 9th EFORT Congress

May 29 - June 1, 2008
Nice, France

Rivaroxaban data from the RECORD4 clinical trial have been presented at the annual meeting of the European Federation of National Associations of Orthopaedics and Traumatology (EFORT).

Friday, May 30, 2008 at 05:30 p.m. CEST (3:30 p.m. GMT):
Investor Conference Call - Review of Rivaroxaban Data at EFORT Congress


Alexander G.G. Turpie, M.D., Chair of the steering committee and lead investigator RECORD4 study
Dr. Kemal Malik, Head of Global Development at Bayer Schering
Dr. Frank Misselwitz, Head Therapeutic Area Cardiovascular, Global Clinical Development
Dr. Alexander Rosar, Head of Investor Relations

MP3 audio recording (presentation and discussion)

Background Information
About RivaroxabanDownload (PDF, 79 KB) collect
About RECORD StudiesDownload (PDF, 61 KB) collect
About Rivaroxaban Clinical StudiesDownload (PDF, 68 KB) collect
History Of AnticoagulantsDownload (PDF, 350 KB) collect
Understanding Venous Blood ClotsDownload (PDF, 51 KB) collect
GlossaryDownload (PDF, 38 KB) collect

List of EFORT 2008 Abstracts on Rivaroxaban

Prevention of venous thromboembolism with rivaroxaban after total hip replacement: economic impact of extended thromboprophylaxis

Rivaroxaban for prevention of venous thromboembolism after total hip replacement: impact on healthcare costs based on the RECORD1 study

Rivaroxaban for thromboprophylaxis after total knee replacement: the RECORD3 trial

Comparison of rivaroxaban – an oral, direct Factor Xa inhibitor – and subcutaneous enoxaparin for thromboprophylaxis after total knee replacement (RECORD4: a phase III study)

Comparison of oral rivaroxaban and subcutaneous enoxaparin for extended thromboprophylaxis following total hip replacement: RECORD1

An evaluation of the efficacy and safety of extended thromboprophylaxis with oral rivaroxaban compared with short-term subcutaneous enoxaparin following total hip replacement (RECORD2: a phase III study)